Bridion

Sugammadex

Reversal of rocuronium- or vecuronium-induced neuromuscular blockade in patients ≥2 yr.

IV Single bolus inj given rapidly, w/in 10 sec into existing IV line. Adult Routine reversal 4 mg/kg if recovery reached at least 1-2 post-tetanic counts (PTC) or 2 mg/kg if spontaneous recovery occurred up to reappearance of T₂ following rocuronium- or vecuronium-induced blockade. Immediate reversal of rocuronium-induced blockade 16 mg/kg administered 3 min after bolus dose of rocuronium Br 1.2 mg/kg. Recurrence of neuromuscular blockade post-op Repeat dose of 4 mg/kg after initial dose of 2 mg/kg or 4 mg/kg. Childn & adolescent ≥2 yr Routine reversal of rocuronium- or vecuronium-induced blockade 4 mg/kg if recovery reached at least 1-2 PTC or 2 mg/kg at re-appearance of T₂.

Hypersensitivity.

Hypersensitivity including anaphylactic reactions. Not to be used to reverse block induced by nonsteroidal neuromuscular blockers (eg, succinylcholine or benzylisoquinolinium compd) or steroidal neuromuscular blockers other than rocuronium or vecuronium; reversal of pancuronium-induced blockade. Prolonged aPTT & PT (INR); marked bradycardia. Increased risk of recurrence of neuromuscular blockade w/ low doses. Signs of light anesth when neuromuscular blockade was reversed intentionally in the middle of anesth. Waiting times for re-administration w/ neuromuscular blocking agents. Patients receiving rocuronium or vecuronium in ICU setting; on controlled Na diet. Delayed recovery time in CV disease, elderly or edematous state. Provide adequate ventilation. Monitor coagulation parameters in patients w/ known coagulopathies & those using anticoagulants; hemodynamic changes during & after reversal. Monitor for signs of recurrence of neuromuscular blockade approx up to 15 min after parenteral administration of another medicinal product occurring w/in 7.5 hr. Concomitant use w/ medicinal products which potentiate neuromuscular blockade in post-op period; hormonal contraceptives; toremifene & fusidic acid. Not recommended in severe renal impairment including those requiring dialysis (CrCl <30 mL/min). Severe hepatic impairment or hepatic impairment accompanied by coagulopathy. Pregnancy & lactation. Immediate reversal in childn & adolescents. Not recommended in term newborn infants (<30 days) & infants (30 days to 2 yr).

Airway complication of anesth, anesth complication, procedural hypotension & complication; cough.

Displacement of vecuronium or rocuronium w/ toremifene. Delayed recovery time w/ IV fusidic acid. Reduced effectiveness of hormonal contraceptives eg, progestogen. Interference w/ serum progesterone assay.

Antidotes & Detoxifying Agents

V03AB35 - sugammadex ; Belongs to the class of antidotes. Used to reverse neuromuscular blockade caused by rocuronium or vecuronium.

S